FDA actions and evidence shifts that affect peptides and GLP-1s — dated, primary-sourced, and confidence-flagged. We don’t embellish, and we mark exactly how solid each item is.
Last reviewed June 13, 2026
How to read this. DoseCraft sells no compounds, so FDA enforcement aimed at sellers does not apply to us — we surface it because it affects the landscape you operate in. Each item carries a confidence flag and, where the claim is contested or its relevance is indirect, an explicit caveat.
EvidenceHigh confidenceMay 29, 2026 · STAT News
GLP-1 'microdosing' trend has no long-term evidence and no agreed definition
Reporting on the surging GLP-1 microdosing trend, STAT News states there are 'no legitimate long-term data to support it… not even a single definition of microdosing,' and that it is promoted on social media for perceived — but unproven — longevity and anti-inflammatory benefits. Cedars-Sinai, Cleveland Clinic and UCLA Health describe the practice as experimental and unauthorized.
Why it matters for you
This is the kind of evidence-vacuum trend DoseCraft labels honestly. In our three-lane model a use case like this sits in the Experimental lane, not the Clinical lane — clearly marked so you know what you're looking at before you act.
FDA warns 30 telehealth companies over illegal marketing of compounded GLP-1s
The FDA issued a second group of warning letters to 30 telehealth companies for illegally marketing compounded GLP-1 products, citing unapproved-drug and misbranding violations. The agency characterised this wave as larger than the entire preceding decade of comparable action.
Why it matters for you
These letters target sellers and marketers of compounded drugs. DoseCraft sells no compounds and provides education and tracking only — so the action does not apply to DoseCraft. We surface it because it directly affects where and how the compounded-GLP-1 telehealth segment can operate, which matters if you source through those channels.
Caveat. FDA's own 'thousands of letters' framing is disputed in magnitude — independent trackers counted roughly 61 formally posted as of late 2025, and most volume was untitled rather than formal warning letters. The enforcement is real and escalating; the exact count is contested.
MarketMedium confidenceFebruary 23, 2026 · MIT Technology Review
Independent testing finds grey-market peptide quality is widely unreliable
MIT Technology Review documented an HPLC-based independent testing service (Finnrick) reporting endotoxin contamination in a meaningful share of tested vials and BPC-157 samples that scored zero for active compound. The dataset has grown since publication.
Why it matters for you
Product quality, not regulatory status, is the dominant real-world risk for grey-market peptides. DoseCraft's job is to label evidence honestly and never to sell you a compound — so our guidance is structurally free of any incentive to push a product onto you.
Caveat. Specific contamination percentages drift as the dataset grows and depend on the testing service's vendor sample. Treat the direction (quality is unreliable) as well-supported and any single percentage as a snapshot. Earlier-circulated figures such as a '41% fabricated COA' rate failed independent verification and are deliberately NOT cited here.
Every compound in DoseCraft is sorted into Clinical, Expert, or Experimental by the strength of its evidence — and we sell none of them. See exactly how we decide.
Not medical or legal advice — educational only. This tracker summarizes public regulatory and research developments for context. Peptide regulations vary by jurisdiction; research your local laws and consult a licensed professional before acting.
We use a few cookies to see what's helpful and make the site better. You can change your mind anytime.